GlassScriptPhysician profile
Angelo Junard Lewis
NPI 1669142527
$11,825.83
in general payments reported to CMS, 2019-2025
33 companies · $2,711 in 2025
The $2,711 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $2,597 · 2023: $2,934 · 2024: $3,170 · 2025: $2,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,511 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,511.31 |
| Education | $303.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,867.88 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,243.54 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,152.82 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Intra-Sana Laboratories | $822.81 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Takeda Pharmaceuticals U.S.A., INC. | $758.54 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Scientific Affairs, LLC | $487.14 | 2022-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $403.45 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $370.41 | 2022-2025 | |
| Vivus LLC | $359.09 | 2021-2025 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $311.71 | 2022-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $303.79 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $289.61 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $270.14 | 2022-2025 | Ocaliva |
| Evoke Pharma, INC. | $265.46 | 2021-2025 | Gimoti |
| Phathom Pharmaceuticals, INC. | $257.16 | 2023-2024 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $247.21 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $201.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $194.92 | 2024-2025 | Omvoh |
| Genzyme Corporation | $148.03 | 2022-2024 | |
| Regeneron Pharmaceuticals, INC. | $135.21 | 2022 | |
| Nestle Healthcare Nutrition INC. | $122.89 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $110.06 | 2022 | |
| Celltrion USA INC. | $88.68 | 2024-2025 | Zymfentra, Vegzelma |
| Braintree Laboratories, INC. | $72.14 | 2023-2024 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $55.35 | 2022-2023 | Dificid |
| Lucid Diagnostics INC. | $54.49 | 2024-2025 | |
| Sandoz INC. | $47.15 | 2023 | Hyrimoz |
| Amgen INC. | $46.05 | 2022-2023 | Amjevita, Avsola |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.21 | 2023-2024 | Cyltezo |
| Ferring Pharmaceuticals INC. | $41.86 | 2022-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $24.66 | 2024 | |
| Daiichi Sankyo INC. | $16.73 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.